Compare Match Group Inc (MTCH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Novo Nordisk A/S — how do they compare? Match Group Inc trades at $41.46 (market cap $9.45B), while Novo Nordisk A/S trades at $44.89 (market cap $200.69B). The key difference: Novo Nordisk A/S is far larger — about 21.2× Match Group Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| MTCH | NVO | |
|---|---|---|
Market Cap | $9.45B | $200.69B |
Sector | Media | Health |
52-Week High | $42.44 | $63.98 |
52-Week Low | $28.90 | $35.29 |
Enterprise Value | $12.41B | $215.49B |
Dividend Yield | 1.94% | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.15, down 1.7% today, near the analyst low target of $41.00. The stock shows a bullish technical trend with recent earnings beating expectations in Q2 2026. Fundamentals are solid with a P/E of 14.59, net income margin of 20.17%, and strong cash flow growth. Recent news highlights AI-driven product innovations at Tinder and institutional buying interest.
Outlook is positive with a consensus price target of $42.50, offering modest upside. Key opportunities include AI integration and user growth, while risks involve high debt levels and competitive pressures in the dating app market. The stock presents a balanced risk-reward profile for growth-oriented investors.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
